Leede Financial Issues Pessimistic Outlook for CRDL Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at Leede Financial decreased their FY2027 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued on Tuesday, November 19th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.16 for the year, down from their prior forecast of $0.18. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. Leede Financial also issued estimates for Cardiol Therapeutics’ FY2028 earnings at $0.74 EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a research note on Wednesday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Cardiol Therapeutics presently has an average rating of “Buy” and an average target price of $8.75.

Cardiol Therapeutics Stock Up 1.0 %

CRDL opened at $1.58 on Wednesday. The business’s fifty day simple moving average is $1.97 and its 200 day simple moving average is $2.08. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 52 week low of $0.79 and a 52 week high of $3.12. The firm has a market cap of $128.52 million, a P/E ratio of -4.00 and a beta of 0.91.

Institutional Trading of Cardiol Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. AdvisorShares Investments LLC boosted its holdings in shares of Cardiol Therapeutics by 12.7% during the second quarter. AdvisorShares Investments LLC now owns 1,466,972 shares of the company’s stock valued at $2,934,000 after acquiring an additional 164,994 shares during the period. Foundations Investment Advisors LLC lifted its position in Cardiol Therapeutics by 237.4% in the 3rd quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock valued at $321,000 after purchasing an additional 113,950 shares during the last quarter. Lion Street Advisors LLC lifted its position in Cardiol Therapeutics by 31.4% in the 2nd quarter. Lion Street Advisors LLC now owns 253,281 shares of the company’s stock valued at $505,000 after purchasing an additional 60,581 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in Cardiol Therapeutics in the 2nd quarter valued at about $59,000. Finally, Jane Street Group LLC bought a new stake in Cardiol Therapeutics in the 3rd quarter valued at about $29,000. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.